AR110730A1 - LISTERY AND METHOD RECOMBINANT VACCINE VACCINES FOR USE IN CANCER IMMUNOTHERAPY - Google Patents
LISTERY AND METHOD RECOMBINANT VACCINE VACCINES FOR USE IN CANCER IMMUNOTHERAPYInfo
- Publication number
- AR110730A1 AR110730A1 ARP180100032A ARP180100032A AR110730A1 AR 110730 A1 AR110730 A1 AR 110730A1 AR P180100032 A ARP180100032 A AR P180100032A AR P180100032 A ARP180100032 A AR P180100032A AR 110730 A1 AR110730 A1 AR 110730A1
- Authority
- AR
- Argentina
- Prior art keywords
- methods
- nucleic acids
- subject
- recombinant
- fusion polypeptides
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/86—Lung
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
En la presente se proporcionan polipéptidos de fusión recombinantes que comprenden un péptido antigénico HPV16 y un péptido antigénico HPV18, donde el péptido antigénico HPV16 y el péptido antigénico HPV18 están enlazados operativamente en tándem (p. ej., fusionados a un péptido que contiene PEST). También se proporcionan ácidos nucleicos que codifican estos polipéptidos de fusión, cepas de bacterias o de Listeria recombinantes que comprenden tales polipéptidos de fusión o tales ácidos nucleicos y bancos. de células que comprenden tales cepas de bacterias o de Listeria recombinantes. En la presente también se proporcionan métodos para generar tales polipéptidos de fusión, tales ácidos nucleicos y tales cepas de bacterias o de Listeria recombinantes. También se proporcionan composiciones inmunogénicas, composiciones farmacéuticas y vacunas que comprenden tales polipéptidos de fusión, tales ácidos nucleicos o tales cepas de bacterias o de Listeria recombinantes. También se proporcionan métodos para inducir una respuesta inmunitaria antigénica asociada antitumoral en un sujeto, métodos para inducir una respuesta inmunitaria antitumoral o anticáncer en un sujeto, métodos para tratar un tumor o cáncer en un sujeto, métodos para prevenir un tumor o cáncer en mi sujeto, y métodos para proteger a un sujeto contra un tumor o cáncer usando tales polipéptidos de fusión recombinantes, ácido nucleicos, cepas de bacterias o Listeria recombinantes, composiciones inmunogénicas, composiciones farmacéuticas o vacunas.Recombinant fusion polypeptides are provided herein that comprise an HPV16 antigenic peptide and an HPV18 antigenic peptide, where the HPV16 antigenic peptide and the HPV18 antigenic peptide are operably linked in tandem (e.g., fused to a PEST-containing peptide) . Nucleic acids encoding these recombinant polypeptides, recombinant bacteria or Listeria strains comprising such fusion polypeptides or such nucleic acids and banks are also provided. of cells comprising such recombinant bacteria or Listeria strains. Also provided herein are methods for generating such fusion polypeptides, such nucleic acids and such recombinant bacteria or Listeria strains. Immunogenic compositions, pharmaceutical compositions and vaccines comprising such fusion polypeptides, such nucleic acids or such recombinant bacteria or Listeria strains are also provided. Methods are also provided to induce an associated antitumor immune response in a subject, methods to induce an antitumor or anticancer immune response in a subject, methods to treat a tumor or cancer in a subject, methods to prevent a tumor or cancer in my subject , and methods for protecting a subject against a tumor or cancer using such recombinant fusion polypeptides, nucleic acids, recombinant bacteria or Listeria strains, immunogenic compositions, pharmaceutical compositions or vaccines.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762442940P | 2017-01-05 | 2017-01-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR110730A1 true AR110730A1 (en) | 2019-04-24 |
Family
ID=62790883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180100032A AR110730A1 (en) | 2017-01-05 | 2018-01-05 | LISTERY AND METHOD RECOMBINANT VACCINE VACCINES FOR USE IN CANCER IMMUNOTHERAPY |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR110730A1 (en) |
| TW (1) | TW201833323A (en) |
| WO (1) | WO2018129306A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9012141B2 (en) | 2000-03-27 | 2015-04-21 | Advaxis, Inc. | Compositions and methods comprising KLK3 of FOLH1 antigen |
| CN106459887A (en) | 2014-04-24 | 2017-02-22 | 阿德瓦希斯公司 | Recombinant listeria vaccine strains and methods of producing the same |
| MA41644A (en) | 2015-03-03 | 2018-01-09 | Advaxis Inc | LISTERIA-BASED COMPOSITIONS INCLUDING A MINIGEN EXPRESSION SYSTEM CODING PEPTIDES, AND METHODS OF USE THEREOF |
| KR20190082850A (en) | 2016-11-30 | 2019-07-10 | 어드박시스, 인크. | Immunogen compositions targeting repeated cancer mutations and methods of using the same |
| SG11202002157TA (en) | 2017-09-19 | 2020-04-29 | Advaxis Inc | Compositions and methods for lyophilization of bacteria or listeria strains |
| CN112074737A (en) * | 2018-03-09 | 2020-12-11 | 阿德瓦希斯公司 | Compositions and methods for evaluating listeria strains for attenuation and infectivity |
| CN111269868A (en) * | 2019-12-10 | 2020-06-12 | 浙江农林大学 | Construction method and application of attenuated Listeria monocytogenes |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10010593B2 (en) * | 2014-10-14 | 2018-07-03 | The Trustees Of The University Of Pennsylvania | Recombinant Listeria vaccine strains and methods of using the same in cancer immunotherapy |
| WO2016183361A1 (en) * | 2015-05-13 | 2016-11-17 | Advaxis, Inc. | Immunogenic listeria-based compositions comprising truncated acta-antigen fusions and methods of use thereof |
| AU2016340148A1 (en) * | 2015-10-14 | 2018-05-31 | Advaxis, Inc. | Recombinant Listeria strains and methods of using the same in cancer immunotherapy |
-
2018
- 2018-01-05 AR ARP180100032A patent/AR110730A1/en unknown
- 2018-01-05 WO PCT/US2018/012570 patent/WO2018129306A1/en active Application Filing
- 2018-01-05 TW TW107100492A patent/TW201833323A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201833323A (en) | 2018-09-16 |
| WO2018129306A1 (en) | 2018-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR110730A1 (en) | LISTERY AND METHOD RECOMBINANT VACCINE VACCINES FOR USE IN CANCER IMMUNOTHERAPY | |
| MX2020004829A (en) | Immunogenic heteroclitic peptides from cancer-associated proteins and methods of use thereof. | |
| MA40228A (en) | Recombinant listeria strain expressing heterologous antigen fusion proteins and methods of use thereof | |
| NZ753307A (en) | Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof | |
| MX2019000215A (en) | Listeria-based immunogenic compositions comprising wilms tumor protein antigens and methods of use thereof. | |
| CR20180027A (en) | NEW PEPTIDES AND NEW COMBINATIONS OF PEPTIDES FOR USE IN THE SAME THERAPY AGAINST OVARY EPITELIAL CANCER AND OTHER TYPES OF CANCER. | |
| SG10201903349YA (en) | Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy | |
| MX2017008187A (en) | Combination of listeria-based vaccine with anti-ox40 or anti-gitr antibodies. | |
| MX2017000836A (en) | Listeria-based immunogenic compositions for eliciting anti-tumor responses. | |
| MX2018004598A (en) | Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy. | |
| CR20180174A (en) | NEW PEPTIDES, COMBINATIONS OF PEPTIDES AND SUPPORTS FOR USE IN THE IMMUNOTHERAPEUTIC TREATMENT OF VARIOUS TYPES OF CANCER | |
| TW201613956A (en) | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL) | |
| CR20160018A (en) | NEW IMMUNOTHERAPY AGAINST VARIOUS TUMORS LIKE CANCER OF LUNG, INCLUDING THE CARCINOMA OF PULMON AMICROCÍTICO (NSCLC) | |
| MX2023006203A (en) | Novel vaccines against zika virus. | |
| RU2016145464A (en) | RECOMBINANT VACCINE LISTERIA STRAINS AND METHODS FOR THEIR OBTAINING | |
| CL2019000704A1 (en) | Canine adenovirus vectors. | |
| WO2019006401A3 (en) | Listeria-based immunogenic compositions comprising heteroclitic wilms tumor protein antigens and methods of use thereof | |
| MX2018003352A (en) | Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy. | |
| BR112017002206A2 (en) | koc1-derived peptide and vaccine including the same | |
| EP4219525A3 (en) | Foxm1-derived peptide, and vaccine including same | |
| WO2015149016A3 (en) | Breast and ovarian cancer vaccines | |
| WO2016011432A3 (en) | Identification of immunogenic mhc class ii peptides for immune-based therapy | |
| AR092320A1 (en) | PEPTIDES THAT INDUCE IN FISH AN IMMUNE RESPONSE AGAINST COPEPODES AND / OR A MUCOUS SHIELD, VACCINES, USES AND METHODS TO MODULATE THE IMMUNE RESPONSE OF A FISH AND / OR INDICATE THE GENERATION OF A MUCOUS SHIELD | |
| EP4282883A3 (en) | Cdca1-derived peptide and vaccine containing same | |
| BR112017002193A2 (en) | urlc10-derived peptide and vaccine containing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |